ARTHUR J. WEISS, M.D.; LAIRD G. JACKSON, M.D.; RALPH CARABASI, M.D.
Until recently, it was believed that preformed pyrimidines, unlike preformed purines, were not utilized by mammalian tissues, either normal or neoplastic. In 1954, Rutman, Cantarow, and Paschkis (1) observed that uracil was incorporated into preneoplastic rat liver and rat hepatoma. In 1957, Heidelberger, Leibman, Harbers, and Bhargava (2) verified this finding and noted that significant incorporation of uracil occurred into intestinal mucosa and several carcinomas of mice and rats. Because of these findings, many pyrimidine antagonists have been synthesized and evaluated for their effect in malignant disease. Of these drugs, 5-fluorouracil (3), 5-fluorodeoxyuridine (4), and 6-azauridine (5) have been subjected
Learn more about subscription options.
Register Now for a free account.
WEISS AJ, JACKSON LG, CARABASI R. An Evaluation of 5-Fluorouracil in Malignant Disease. Ann Intern Med. 1961;55:731–741. doi: 10.7326/0003-4819-55-5-731
Download citation file:
Published: Ann Intern Med. 1961;55(5):731-741.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only